Category: Ocrevus

Press Release: FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis

Ocrevus Zunovo™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, like at a…

Stuart Schlossman

New Data Shows Positive Efficacy and Safety Outcomes After 10 Years of Ocrevus Treatment

 October 18, 2023 Rosanna Sutherby, Pharm.D. In 2017, the FDA approved Genentech’s Ocrevus (ocrelizumab) for the treatment of relapsing forms…

Stuart Schlossman

First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity

 October 10, 2023 Black and Hispanic / Latinx people with multiple sclerosis (MS) often experience more severe disease and greater…

Stuart Schlossman

Ocrelizumab and Rituximab Demonstrate Similar Safety, Efficacy in Treatment of Multiple Sclerosis

 Treatment with either rituximab and ocrelizumab, 2 FDA-approved therapies that target CD20, resulted in similar odds of experiencing a clinical…

Stuart Schlossman

Peace out: Roche’s Genentech adopts V hand signal in next-gen Ocrevus campaign for multiple sclerosis

Beth Snyder Bulik -Senior Editor The two-finger V sign debuted in Roche’s Genentech first TV commercial for multiple sclerosis treatment…

Stuart Schlossman

Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers – PubMed

 Monica Margoni 1 2, Paolo Preziosa 1 3, Paola Tortorella 4, Massimo Filippi 1 3 5 6 7, Maria A Rocca 8 9 10 Affiliations expand PMID: 35668317   DOI: 10.1007/s13311-022-01252-5 Abstract Multiple sclerosis (MS) is a chronic inflammatory, demyelinating,…

Stuart Schlossman

MS patients treated with rituximab may receive COVID-19 vaccine as soon as possible

 May 17, 2022 Rituximab-treated patients with MS may be vaccinated for COVID-19 as soon as possible, researchers reported in JAMA Network…

Stuart Schlossman

New Data for Genentech’s Ocrevus (Ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis

  75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression…

Stuart Schlossman

Ocrelizumab Data Go Against Traditional Conceptions of Wearing Off Effect

 November 18, 2021  – Marco Meglio Ilya Kister, MD, professor of neurology, NYU Grossman School of Medicine, discussed his surprising…

Stuart Schlossman

Genentech to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryng (satralizumab-mwge) in Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2021

 Ocrevus data to show sustained reduction in disability progression through 8 years for primary progressive multiple sclerosis (PPMS) and 7.5…

Stuart Schlossman

Categories

Latest Blog Posts